1 Essential Standard Operating Procedures Sample Templates Table of Contents Introduction Study Conduct and Good Clinical Practice 1: JHM Training/Certification Documentation 2: Delegation of Responsibility 3: Process for Obtaining Informed Consent 4: Documenting Informed Consent 5: Documenting Eligibility Assessment 6: Submitting Changes in Research 7: Protocol Deviation Reporting and Documentation 8: Reporting Study Non-Compliance 9: Reporting Unanticipated Problems/Events 10: Reporting the Death of a JHM Research Participant Subject Information/Data 11: Study Subject Data Collection 12: Paper Case Report Form Design and Use 13: Site Generated Electronic Case Report Forms FDA Regulated Studies and Principal Investigator Responsibilities 14: Responsibilities for FDA Regulated Research 15: Required Reporting to FDA IND Studies 16: Sponsor-required Written General Monitoring Plan for FDA IND Studies 17: Drug Accountability 18: Required Reporting to FDA IDE Studies 19: Sponsor-required Written General Monitoring Plan for FDA IDE Studies 20: IDE Device Accountability - Receipt and Storage 21: IDE Device Accountability - Usage of Device 22: IDE Device Accountability Device Return Regulatory Procedures 23: Regulatory Documentation Organization 24: Retention of Study Records 25: Writing Standard Operating Procedures 26: Note-to-File
2 JHM IRB COMPLIANCE GUIDE FOR DEVELOPING STANDARD OPERATING PROCEDURES INTRODUCTION The Compliance Monitoring Team has created Standard Operating Procedure templates (SOPs) in response to action items discovered in IRB directed audits, FDA audit and site visits, and routine monitoring visits. These templates were designed in order to assist researchers in establishing their own set of rules, or SOP criteria, and to help study staff operate their respective studies in an organized and consistent manner, that demonstrates adherence to Federal regulations and Institutional guidance. The SOP templates and the corresponding Case Report Form/checklists cover the basic categories of study procedures and can be applied across studies. SOP samples are available below. Samples of the SOPs listed here include: How to obtain Informed Consent from research subjects Documenting the Informed Consent process Maintaining Regulatory Documents Study Record retention Serious Adverse Event reporting Safety Reporting for routine Adverse Events and Protocol Deviations The templates follow a formal format that includes the following structure: I. A header indicating the title, date, author, version number, pages, and approval information (if applicable). II. The body of the document includes the purpose, scope, references (if applicable), and a number of detailed procedures. When developing your own specific SOPs, you may consider using a less formal structure. If your study requires more specific content, please consider tailoring your individual site and/or protocol Standard Operating Procedures to suit your needs. Other areas to consider when designing your site-specific SOPs: Communication Procedures (IRB, NIH, FDA, Sponsor, other) Protocol Continuing Renewal Protocol Termination IND Safety reports IND Annual reports IND Sponsor-required Written General Monitoring Plan IDE Progress Reports IDE Unanticipated Adverse Device Effect Reporting IDE Sponsor-required Written General Monitoring Plan Withdrawal of Subjects Oral Consent process Assent and Consent of Minors Change In PI /Inherited studies DSMB Reporting requirement
3 Standard Operating Procedures: JHM Training/Certification Documentation The Principal Investigator is responsible for: Approved by: 1. Completing and passing the following training modules: a. Human Subjects Research Compliance b. Course on Research Ethics (C.O.R.E) c. Conflict of Interest d. HIPAA and Research Course 2. Designating study personnel as consent designees who, upon being approved by the IRB to obtain informed consent, shall receive training in the consent process. 3. Assuring the training of all applicable research personnel regarding study procedures, study conduct, and research compliance. 4. Performing additional training and certification as required by the Institution, sponsor, or other regulatory authorities, with such certificates retained for verification. 5. Maintaining a record for all Research Personnel of all training certifications, including all certificates of completion of applicable training modules and, if necessary, any sponsor required documents (e.g., CVs) in the Regulatory Binder. Use the specific table template found in section II.B.2 of this manual.
4 Standard Operating Procedures: Delegation of Responsibility The Principal Investigator is responsible for: 1. Designating all Co-Investigators and other research personnel on the initial review application submitted to the IRB. 2. Ensuring that co-investigators have read and understood the protocol and their specific role in the research, and all other study-related materials (e.g., the investigator brochure, if applicable). 3. Assigning specific tasks and responsibilities for each member of the study team; and communicating and providing training for these roles and responsibilities to each member. 4. Authorizing all members of the study team, who are included in the initial application or later added to the protocol, to perform specific study related tasks but only after receiving approval from the IRB. 5. Maintaining a study responsibility delegation table on which all study team members are named, their respective duties/tasks are outlined, and each member s entry is signed and dated to indicate the team member s willingness to perform his/her designated tasks. Use the specified table found in Section II.B.1 in this manual.
5 Standard Operating Procedures: Process for Obtaining Informed Consent The Principal Investigator and IRB approved study staff members are responsible for: 1. Describing in the IRB application (eforma) how, when, and where, and by whom informed consent will be obtained. In addition, establishing the following elements to the informed consent process: a. Presenting the research subject with adequate opportunity to read the entire informed consent form before it is signed, which may include taking the document home to discuss with family, prior to signing. b. Allowing the subject and/or subject s legally authorized representative ample time and opportunity to ask questions about the study. All questions should be answered to the satisfaction of the subject and/or the subject s legally authorized representative. c. Assessing and confirming the subject s comprehension of the Informed Consent Form content. d. Obtaining legally effective informed consent (i.e. signed, dated and, if applicable, witnessed) from the subject or the subject s legally authorized representative, prior to the initiation of any study specific procedures. 2. Implementing and consistently following the IRB approved consent process. 3. Training, if applicable, study team member approved as consent designees on the process of obtaining informed consent. 4. Signing and dating the IRB approved written informed consent form on the same day as the subject and/or the subject s legally authorized representative. 5. Giving a copy of the informed consent form, signed by the subject, to the subject, and filing another in the subject s medical record (if applicable); the original should remain in the subject s research record.
6 Standard Operating Procedures: Documenting Informed Consent The Principal Investigator is responsible for: 1. Documenting the IRB approved informed consent process was followed by recording and confirming the following information: a. The current IRB approved (noting the version number and expiration date) consent form was used, and signed by the subject; b. The name of the person who discussed the consent form with the potential subject; c. The name of the person who obtained the consent form signature(s) from the research subject (additional witness, or proxy); or why it was not obtained; d. The date of subject and investigator (or IRB approved consent designee) signatures; e. Verification that a copy of the signed consent was given to the subject, that the original remains in the research record, and that a copy is filed in the medical record, if applicable. 2. Verifying the validity of the informed consent form, and assuring proper completion of the approved informed consent process, using the Informed Consent Process checklist found in Section, II.A.1 of this manual. 3. Filing the valid, signed and dated consent form, along with any supporting documentation (e.g., a consent process checklist), in the subject s research record.
7 Standard Operating Procedures: Documenting Eligibility Assessment The Principal Investigator or authorized staff is responsible for: 1. Describing in the IRB application (eforma) all procedures used to determine eligibility and having these procedures approved by the IRB. 2. Completing IRB approved eligibility verification tasks to determine that all study inclusion and exclusion criteria are met prior to study enrollment. 3 Ensuring that appropriate documentation is kept in the subject s research record to confirm study eligibility, including all study-related, clinically obtained information (i.e., source documentation ) used to qualify a subject for study enrollment. 4. Developing and utilizing a study-specific checklist (or sponsor provided form) containing study eligibility criteria, using the template in Section II.A.2 of this manual. This checklist should be signed and dated by the person performing the eligibility assessment and completing the form.
8 Standard Operating Procedures: Submitting Changes in Research The Principal Investigator is responsible for: 1. Requesting and obtaining IRB approval for all proposed changes to the protocol or informed consent form, and documenting IRB approval prior to executing any such changes. 2. Determining the level of modification and describing it to the IRB as: a. A major modification, which involves a change to the protocol and consent, or b. A minor or administrative modification, which may not necessitate a change to the protocol or consent form. 3. Submitting a Change in Research Application to the IRB, accompanied by all documentation affected by the proposed changes, including: a. Sponsor s protocol; or b. IRB Protocol Form A; and/or c. Continuing Review Application (change should be summarized); and/or d. Informed Consent Form; and/or e. Any new documents/materials added to the approved protocol. 4. Retaining in the site s Regulatory File all documentation and IRB correspondence regarding all changes to an approved protocol or consent. 5. Keeping track all modifications to the protocol or consent form, and when such changes were IRB approved, using the Changes in Research Log found in Section II.C.2 in this manual.
9 Standard Operating Procedures: Protocol Deviation Reporting and Documentation The Principal Investigator is responsible for: 1. Conducting the study in accordance with the IRB approved protocol as it is written. 2. Not making any non-emergent changes to, or deviating from, the IRB approved protocol without prior notification to and approval from the IRB as an approved Change in Research. 3. Submitting administrative and minor deviations that precipitate a change to the protocol (per the IRB s flow diagram: and Section IV of this manual) to the IRB for approval using the Changes in Research application. 4. Recording any minor or administrative deviation from the approved protocol that do not precipitate a change to the protocol by utilizing the Deviation Tracking Log found in Section II.C.1 of this manual, and submitting this information to the IRB in the annual continuing review application.
10 Standard Operating Procedures: Reporting Study Non-Compliance The Principal Investigator is responsible for: 1. Notifying the IRB of any incident where the IRB approved protocol was not followed, or Federal, state, and/or Institutional regulatory requirements or directives were overlooked. 2. Informing the IRB of the immediate specific response to reconcile the incident or oversight. 3. Describing to the IRB a corrective action plan, which may include a. site personnel educational/training b. change(s) to the research protocol to minimize the recurrence of incidences of noncompliance.
11 Standard Operating Procedures: Reporting Unanticipated Problems/Events The Principal Investigator is responsible for: 1. Reporting the following specific unanticipated problems or events to the JHM IRB: a. Events such as injuries, side-effects, breaches of confidentiality (including lost/stolen computers, hard copy files, magnetic storage media, etc.), or other problems that 1) harm or increase the risk of harm to the subject or others 2) are unexpected (i.e., not described in the consent form or study) 3) AND are related to research procedure(s). b. New Information that changes the risks or potential benefits of the research as described in the consent form. c. Any FDA restriction on a marketed drug, device, or biologic used in research. d. Any emergent change to the protocol to reduce immediate harm to subject. (Such reports will almost always include a Change to Research application to address the protocol limitation that caused the emergent change.) e. Incarceration of the subject. f. Any event that requires prompt reporting to the study sponsor(s). g. Subject complaint that indicates an unanticipated risk, or remains unresolved by the research team. h. Protocol violation (meaning an accidental or unintentional change to the IRB approved protocol) that placed one or more participants at increased risk, or has the potential to occur again. i. An unexpected adverse device event for IDE studies. 3. Reporting Unanticipated Problems to the IRB promptly, in between 3 and 10 working days, depending upon the seriousness of the problem/event (per the IRB reporting process flow diagram: and Section IV of this manual). 4. Using the most current IRB Unanticipated Problem Event Notification form ( 5. Keeping a log of Unanticipated Problems/Events submitted to the IRB, using the log-sheet found in or Section II.C.3 of this manual.
12 Standard Operating Procedures: Reporting a Death of a JHM Research Participant The Principal Investigator is responsible for: 1. Reporting to the IRB within three (3) working days, the death of a JHM research participant that occurs within 30 days of the study intervention, and that is a. Unexpected and unrelated to the risks described in the IRB approved Informed Consent and protocol, AND b. More likely than not, caused by a research procedure or intervention. 2. Reporting the IRB within ten (10) working days, the death of a JHM research participant that is a. Expected due to the subject s underlying condition or disease state, OR b. Expected as identified as a risk in the approved Informed Consent form and protocol. 3. Reporting to other regulatory authorities (FDA, NIH, etc.) and/or to the Sponsor, if applicable. 4. Recording and retaining all documentation associated with the Death and filing these materials in the Subject s research record.
13 Standard Operating Procedures: Study Subject Data Collection The Principal Investigator and authorized Study Team members are responsible for: 1. Ensuring the accuracy, completeness, legibility, and timeliness of the data entered in sponsor provided Case Report Forms (CRFs) or customized data collection forms, and in all required reports, including logs and checklists. 2. Recording observed data (or data derived from source documents) consistently, or explaining any discrepancies in a Note-to-File, using the template found in Section II.D. of this manual. 3. Designating members of the staff who are authorized to change or correct data entries. 4. Conforming to the following steps in regards to any changes or corrections to a CRF, progress note, research lab result, etc.: a. Draw a single line through the incorrect entry; b. Date and initial the strike-through; c. Enter the correct information and/or explanation proximal to the original entry. d. Instruct staff that correction-fluid cannot be used to make corrections. 5. Establishing a research record review process, to check data accuracy.
14 Standard Operating Procedures: Paper Case Report Form Design and Use The Principal Investigator and authorized Study Team Members are responsible for: 1. Including information in the header of the paper Case Report Form (CRF) to identify the site, the specific protocol title (and study number, if applicable), and the IRB approval number. 2. Creating the body of the CRF to include fields for: a. Unique Subject ID b. Visit Date c. Specific visit number/interval, if applicable d. Section(s) for Visit specific data 3. Using additional space in the footer for signature of study personnel who may complete the CRF, the date of CRF completion, and the Principal Investigator/Co-Investigator s signature to demonstrate a review of the CRF for completion, accuracy, and overall quality control. 4. Completing the CRF in black ink. 5. Making a single line strike-out of the errant data, the necessary correction(s), and the initial and date of the personnel making the correction. Correction-fluid can not be used.
15 Standard Operating Procedures: Site Generated Electronic Case Report Forms The Principal Investigator and authorized Study Team Members are responsible for: 1. Entering information in the site-generated electronic Case Report Form (CRF) or database record to identify the site, the specific protocol title (and study number, if applicable), and the IRB approval number. 2. Completing site-generated CRF or database fields to indicate a. Unique Subject ID b. Visit Date c. Specific visit number/interval, if applicable d. Section(s) for Visit specific data 3. Using additional fields in the electronic CRF record, for the electronic signature of study personnel authorized to complete the CRF, the time/date stamp of CRF completion, and the Principal Investigator/Co-Investigator s electronic signature to demonstrate a review of the CRF for completion, accuracy, and overall quality control. 4. Maintaining an electronic audit trail to keep track of corrections/additions to the database and electronic case report form record(s), who made them, and when via user IDs and time/date stamping routines. 5. Employing adequate security clearance, encryption, archiving, and recovery systems to maximize secure access, subject confidentiality, and record-retention quality assurance.
16 Standard Operating Procedures: Responsibilities for FDA Regulated Research The Principal Investigator conducting IND (new Drug) or IDE (new Device) research is responsible for: 1. Conducting the study in accordance with the most current, IRB approved protocol. 2. Notifying the sponsor (in commercially funded research) prior to making changes to the protocol, except when necessary to protect the safety, rights, or welfare of subjects. 3. Personally conducting or supervising the investigation. 4. Informing the subject that the study drug or device is being used for investigational purposes, and obtaining informed consent. 5. Reporting to the sponsor adverse experiences that occur in the course of the investigation. 6. Reading and understanding the information in the investigator's brochure (For IND/IDE research), including the potential risks and side effects of the drug or device. 7. Ensuring that all associates, colleagues, and employees assisting in the conduct of the study are informed about their obligations in meeting the above commitments. 8. Maintaining adequate and accurate records, and making those records available for inspection by the FDA, Institution, or any authorized regulatory body. 9. Obtaining initial and continuing review and approval of the clinical investigation. 10. Promptly reporting to the IRB all changes in the research activity and all unanticipated problems involving risks to human subjects or others. 11. Awaiting IRB approval, prior to making any changes in the research except where necessary to eliminate apparent immediate hazards to human subjects. 12. Complying with all other requirements regarding the obligations established in 21 CFR Part 312 (Drug research) or 21 CFR 50, 812 (Device research).
17 Sample user Standard Operating Procedure 1 Approved by: Standard Operating Procedure: Establishing a General Monitoring Plan for the FDA IND Application In compliance with 21 CFR and 53, the JHM sponsor/investigator of an Investigational New Drug ( IND ) application is responsible for Procedures: 1. Selecting a Monitor or Monitors to oversee the conduct of the protocol a. The sponsor will designate one or more monitors, as appropriate. i. The sponsor may select an individual to carryout monitoring ii. The sponsor may elect to sub-contract any and all monitoring to a Contract Research Organization (CRO) b. Each monitor shall have proper education, certification, and or other necessary qualifications to perform monitoring duties. c. The Monitor(s) should be chosen based upon the investigation s scope, scale, complexity, investigative agent(s), and disease/condition of the population being studied. d. If applicable to the study, the designated monitor(s) shall remain blinded to study-arm assignments. 2. Establishing a General Monitoring Plan a. The Monitoring Plan can be adapted for the needs of an individual study b. The basic operations of a monitoring plan include i. Designating a monitor or monitors, per Step #1 above ii. Instituting a written Monitoring schedule to review the progress of the study, including 1. A pre-investigation visit to confirm a. the investigator(s) and research site are prepared b. the investigator(s) is(are) aware of the applicable responsibilities, as outlined on FDA Form 1572 and the FDA s monitoring guidance: earchmonitoring/ucm htm c. the study staff is adequately qualified, educated, and/or trained to conduct the study 2. Periodic or interim visits to review and confirm a. regulatory documentation for compliance with all applicable regulations and requirements b. study test-article accountability
18 Sample user Standard Operating Procedure Final Approved by: c. all changes to research have been submitted and approved by the IRB d. the continued adequacy of the facility and its resources for the conduct of the study e. the investigator is following the protocol f. the study team membership and delegation of responsibilities are current and IRB approved 3. Close-out monitoring visit to a. reconcile any outstanding regulatory documentation issues b. resolve outstanding research participant matters (e.g., following adverse events to resolution, outstanding follow-up visits, etc.) c. correct any residual data-queries iii. An inspection of a portion, but not excluding all, of the research subject record for 1. proper informed consent procedures 2. subject eligibility, with source documentation to confirm 3. protocol compliance 4. data integrity, consistency, and correctness 5. safety reporting 6. protocol deviations are noted and reported iv. Generation of a written report identifying the monitoring findings, including 1. What regulatory compliance issues were observed and corrected 2. What research record deficiencies were noted and corrected v. A process for distributing the monitoring report(s) to the sponsor and individual investigator(s) receiving an on-site monitoring visit vi. A monitoring/on-site visit record maintained by the sponsor and/or monitor, documenting 1. When the monitoring was completed 2. Who conducted the monitoring
19 Standard Operating Procedures: Required Reporting for FDA IND/IDE Studies The Principal Investigator, as sponsor-investigator, is responsible for: 1. Determining an event to be a reportable adverse drug reaction as: a. life-threatening (i.e., the subject is at immediate risk of death); and/or b. unexpected (i.e., not known to the PI); and/or c. serious (i.e., resulting in death, hospitalization, disability, or congenital anomaly). 2. Notifying the FDA by phone or fax immediately, but in no more than 7 days, if conditions a, b, or c are established. 3. Completing the FDA MEDWATCH Form 3500A, or a narrative report (identified as an IND Safety Report, if applicable) and submitting the documentation to the FDA as soon as possible, but in no more than 15 days, if the above conditions a, b, or c are established. 4. Submitting supporting documentation for any event that meets the criteria for prompt reporting to the IRB, utilizing the Problem Event Form in the required time-frame. 5. Sending required annual progress and safety summary reports with the FDA, per 21 CFR (IND) or 21 CFR (IDE).
20 Standard Operating Procedures: Drug Accountability The Principal Investigator or authorized Study Team Members, if not utilizing the JHM Investigational Drug Service (IDS), are responsible for: 1. Receiving the study drug a. Maintain adequate records confirming the receipt, shipment, expiration dates, or other disposition information of the investigational drug. b. Documenting any discrepancies. c. Assuring that records include the name of the individual to whom the drug is shipped, the date, quantity, and batch/code number for each shipment. d. Verifying shipment with packing slip or invoices. 2. Storing the study drug a. Securing drug in a locked storage area, and, if applicable, monitoring to assure proper storage conditions. b. Completing regular inventory to assure balance among stock received, dispensed, and returned. 3. Labeling the study drug for product dispensed to subjects a. Prior to dispensing the study drug, generating a label to include the date dispensed; drug name; drug strength, dose, quantity, and expiration information; subject s identifier; PI s contact information; and directions for use. b. Affixing the label to the dispensed drug. 4. Prescribing the study drug a. For all pharmacy-based IND drug studies, completing the Investigational Drug Data Sheet with information on the dispensing procedure and/or the list of authorized prescribers. b. For drug products requiring a prescription, the PI or Co-I will follow applicable JHH and State prescription policies. 5. Dispensing and Drug Disposition with the following information a. Date dispensed/administered b. Patient initials/identifier c. Drug name as defined for this study (does not necessitate unblinding) d. Drug strength (unless blinded) e. Quantity dispensed/administered f. Lot number (unless dispenser is blinded to this) g. Initials of dispenser/person administering drug h. Date and amount of patient returns documented in study records (this is returned drug that cannot be dispensed again) 6. Returning the study drug a. Documenting drug supply return indicating date sent, quantity (including lot numbers), and names of sender and receiver. b. Documenting, if applicable, date, amount, and method of destruction.
21 7. Documenting a. Filing all drug documentation within a dedicated section of the study records. b. Utilizing the IDS Drug Audit form for required procedures. c. Employing a Drug Accountability Log sheet to track items 1-6.
22 Standard Operating Procedures: Required Reporting to FDA for IDE studies The Principal Investigator, as sponsor-investigator, is responsible for: 1. Determining an event to be an Unanticipated Adverse Device Effect as: a. a serious adverse effect upon the subject s health or safety; and/or b. is life-threatening; and/or c. results in death; and d. was unexpected 2. Or determining the event to be a Product Problem that could lead to a death or serious injury if the malfunction were to recur. 3. Completing the FDA MEDWATCH Form 3500A, or a narrative report, and submitting the documentation to the FDA as soon as possible, but in no more than 10 days after discovery of the event. 4. Submitting any supporting documentation for any event that meets the criteria for prompt reporting to the IRB, utilizing the Problem Event Form in the required time-frame. 5. Reporting to any funding agencies, if applicable.
23 Approved by: Standard Operating Procedure: Establishing a General Monitoring Plan for the FDA IDE Application In compliance with 21 CFR (e), 40, and 43, the JHM sponsor/investigator of an Investigational Device Exemption ( IDE ) application is responsible for Procedures: 1. Selecting a Monitor or Monitors to oversee the conduct of the protocol a. The sponsor will designate one or more monitors, as appropriate. i. The sponsor may select an individual to carryout monitoring ii. The sponsor may elect to sub-contract any and all monitoring to a Contract Research Organization (CRO) iii. The name and address of the designated monitor(s) or CRO is to be recorded on the IDE application b. Each monitor shall have proper education, certification, and or other necessary qualifications to perform monitoring duties. c. The Monitor(s) should be chosen based upon the investigation s scope, scale, complexity, investigative agent(s), and disease/condition of the population being studied. d. If applicable to the study, the designated monitor(s) shall remain blinded to study-arm assignments. 2. Establishing a General Written Monitoring Plan as part of the Investigational Plan a. The Monitoring Plan can be adapted for the needs of an individual study b. The basic operations of a monitoring plan include i. Designating a monitor or monitors, per Step #1 above ii. Instituting a Monitoring schedule to review the progress of the study, including 1. A pre-investigation visit to confirm a. the investigator(s) and research site are prepared b. the investigator(s) is(are) aware of the applicable responsibilities from 21 CFR 812 Sub-Part E and the FDA s monitoring guidance: earchmonitoring/ucm htm c. the study staff is adequately qualified, educated, and/or trained to conduct the study
24 Sample user Standard Operating Procedure Approved by: 2. Periodic or interim visits to review and confirm a. regulatory documentation for compliance with all applicable regulations and requirements b. study test-article accountability per 21 CFR 812. c. all changes to research have been submitted and approved by the IRB d. the continued adequacy of the facility and its resources for the conduct of the study e. the investigator is following the protocol f. the study team membership and delegation of responsibilities are current and IRB approved 3. Close-out monitoring visit to a. reconcile any outstanding regulatory documentation issues b. resolve outstanding research participant matters (e.g., following adverse events to resolution, outstanding follow-up visits, etc.) c. correct any residual data-queries iii. An inspection of a portion, but not excluding all, of the research subject record for 1. proper informed consent procedures 2. subject eligibility, with source documentation to confirm 3. protocol compliance 4. data integrity, consistency, and correctness 5. safety reporting 6. protocol deviations are noted and reported iv. Generation of a written report identifying the monitoring findings, including 1. What regulatory compliance issues were observed and corrected 2. What research record deficiencies were noted and corrected v. A process for distributing the monitoring report(s) to the sponsor and individual investigator(s) receiving an on-site monitoring visit vi. A monitoring/on-site visit record maintained by the sponsor and/or monitor, documenting 1. When the monitoring was completed 2. Who conducted the monitoring
25 Standard Operating Procedures: IDE Device Accountability-Receipt and Storage The Principal Investigator is responsible for: 1. Retaining shipping invoices, waybills, manifests, bills of lading, or other documentation verifying the receipt of the Investigational Device(s). 2. Maintaining a record (log) of the receipt of the investigational device(s). The log will be placed in the study regulatory binder and should contain the following information, consistent with retained shipping documentation: a. Date of device receipt b. Batch number or code mark associated with each device c. Type and quantity of the device received d. Name or initials of the person who received the shipment 3. Filing written documentation of any discrepancies between the invoice and what was actually Received and entered into the Device Accountability log. Such documentation should be placed in the study regulatory binder. 4. Storing investigational device separately from other approved devices or standard inventory or stock. a. If the study uses a supply of investigational devices, these will be stored in a locked cabinet that is permanently mounted to the floor or wall. b. If the study uses a large piece of equipment, such as an MRI machine, then the equipment will be maintained in a specified, secure location. 5. Ensuring that the investigational device(s) is (are) labeled in accord with FDA regulations. 6. Ensuring that access to the investigational device(s) is limited to study personnel. 7. Reviewing the device receipt log periodically and, if device stock is maintained, verifying it against the physical count of devices on site.
26 Standard Operating Procedures: Device Accountability-Usage of the Device The Principal Investigator is responsible for: 1. Maintaining an accurate record of the investigational device(s) dispensed and used. The log should be placed in the study regulatory binder and contain the following information: a. The date device dispensed and/or used b. The batch number or code mark of each dispensed device (if applicable) c. The number of devices dispensed (if applicable) d. The name or initials of the person who dispensed or used the device e. The initials or unique study identification number of the study participant receiving the device f. Any repairs or adjustments made to the device(s), with date and time of service 2. Reviewing the device log periodically, and verifying the reported inventory against the stock on hand.
27 Standard Operating Procedures: Device Accountability-Device Return The Principal Investigator is responsible for: 1. Maintaining an accurate record of the return of the investigational device(s) to the study Sponsor. The log should be placed in the study regulatory binder and contain the following information: a. The date of device return to the Sponsor b. The batch number or code mark associated with each returned device c. The number of devices returned to the Sponsor d. The name or initials of the person packaging the devices for return 2. Obtaining written authorization from the Sponsor for alternate disposal, and placing the authorization on file in the study regulatory binder, if the device(s) is (are) not returned to the Sponsor.
28 Standard Operating Procedures: Regulatory Documentation Organization The Principal Investigator and authorized Study Team Members are responsible for: 1. Assembling a binder or electronic database in which to file all regulatory documentation. The minimum recommended material included should be: a. A Table of Contents b. A copy of the original human subjects research application submitted to the JHM IRB (and, if applicable, the application may be located in eirb) c. A copy of the sponsor's protocol (if applicable) d. A copy of the federal grant application (if applicable) e. A copy of the investigator's brochure for an investigational new drug (if applicable) f. A copy of the investigational device exemption information (if applicable) g. A copy of an investigator-initiated IND or IDE application (if applicable) h. A copy of the IRB approved Informed Consent form (if applicable) i. A copy of all correspondence with the IRB, sponsor, funding source, FDA, or others j. Monitoring/Auditing documentation 2. Filing the documents in date order. 3. Maintaining the binder, for paper records, in a secure location. 4. Maintaining secure electronic records from which regulatory documents may be retrieved, viewed, and printed, if necessary for monitoring/auditing purposes.
29 Standard Operating Procedures: Retention of Study Records The Principal Investigator is responsible for: 1. Maintaining all research records according to local, Institutional (Cf. onduct.html#data), and Federal requirements, and storing them in a securely. 2. Storing study records for ANY study that involves private health information and is subject to the HIPAA Privacy Rules, for seven years after the last subject has completed the study. 3. Storing all study records for studies involving an Investigational New Drug (IND) for the FDA required period of two years after the approval of the study drug, or the delivery of the study drug is discontinued. 4. Storing all study records for studies involving an Investigational Device Exemption (IDE) for the FDA required period of two years after the study is terminated/completed, or when a PMA application supporting data is not necessary. 5. Storing study records for research on children at the School of Medicine until the pediatric subject reaches the age of 21.
30 Standard Operating Procedures: Writing Standard Operating Procedures (SOPs) The Principal Investigator or authorized Study Team Member should delineate study procedures and regulatory processes in a standard format: 1. Structure Elements a. Use a header, which may include the principal investigator s name, and department information; page number, the SOP s title, version number, approval date, and the name of the person authorized to approve the SOP. b. An optional Purpose section may be used to summarize how to use the SOP. c. An optional Scope may be used to indicate to whom the SOP applies. d. Develop a detailed Procedures section to delineate all the steps to perform a specific procedure. 2. Documentation Organization and Quality Assurance a. The site should use the most current versions of the SOPs b. Previous versions of the SOPs should be available for Quality Assurance audits, using the Version Number to provide an audit trail. b. A binder or electronic file should contain copies of all SOPs. c. The Principal Investigator should review the SOPs for adequacy and applicability.
31 Standard Operating Procedures: Note-to-File The Principal Investigator and/or authorized study personnel may generate a Note-to-File to provide information or clarification concerning a study-related issue. It should include the following elements: 1. Header information indicating the date of the Note-to-File, the study to which it pertains, who is completing the document, and where it is filed. 2. A narrative explanation describing: a. The specific recent event or new information necessitating the creation of the Note-to-File. b. The details of the immediate response or resolution to the event, or outcome to the new information. c. A revision to the protocol or quality assurance mechanism to demonstrate a systematic corrective action to improve the conduct or organization of the study. d. A confirmation that all information has been appropriately reported to all required recipients, per applicable regulations and guidelines. 3. A signature and date of the study-team member generating the Note-to-File. 4. A signature and date of the Principal Investigator, confirming review of the report.
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
FDA Audit Guidelines University of Miami Office of the Vice Provost for Research FDA Audit Guidelines Contents INTRODUCTION 3 VICE PROVOST FOR RESEARCH ROLE IN FDA AUDITS 3 PRE-AUDIT REVIEW 3 INSPECTION
Data Management DM 401.00 STANDARD OPERATING PROCEDURE FOR Data Management Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell, MD, FACP
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky I. Compliance with IRB and Applicable Federal Requirements A. Investigators
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
Essential Documents for the Conduct of a Clinical Trial Debra Dykhuis Associate Director RSO Introduction Rationale for choosing this topic AHC movement toward setting GCP (Good Clinical Practice) guidelines
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
Comprehensive Study Documents List (Biomedical Studies) Investigators conducting human subjects research must maintain study documents in adherence to federal and state regulations, USC policies, and good
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives
PROTOCOL DEVIATIONS 229 1 of 7 PURPOSE The purpose of this policy is to define protocol deviations and the subsequent actions required by the Principal Investigator (PI) once a protocol deviation occurs
DHHS/NIH/OD/OIR/OHSRP 1/2/2015 The audience for this course is Principal Investigators (PIs), investigators and Research Coordinators (RCs) serving on the study team of human clinical studies and trials.
NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of
CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL #  [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities
Planning for FDA Clinical Site Inspections: Are You at Risk? Catherine M. Anderson, Ph.D., RAC 29 April 2010 Outcome of FDA Inspections (2005-2009)* 5.1 44.5 * Based on 1747 site inspections from 2005-2009
Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Introduction The purpose of this module is to provide a basic understanding of the responsibilities of the principal
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Effective Date: 09/12/06, 08/02/10, 3/2/11 Title: 1.0 OBJECTIVE: 1.1 This SOP describes the methods and policies for: Handling investigational drug Dispensing investigational drug 1.2. This procedure applies
Name of Organization Providing IRB Review: Stony Brook University ( SBU IRB ) Name of Institution Relying on the SBU IRB ( Institution ): Latest AAHRPP Accreditation Date (if applicable) OHRP Federal Wide
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records
Music No audio Please review information shown to understand the general course navigation and available resources. Resources, such as the audio script, example forms, and website links, can be accessed
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
Investigator Responsibilities in Clinical Research: Insights and helpful hints for researchers ITHS Clinical Research Education Series September 7, 2010 Objectives Understanding the requirements of DHHS
Investigator Responsibilities Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 010 Version number: 1 Effective date: 01 June 2010 Review due: May 2011
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
Tool Summary Sheet Tool: Extramural Essential Documents Binder/File Tabs Purpose: To provide an organizational framework and guidance for filing paper versions of essential study documents (or referencing
SUBJECT: Principal Investigator Oversight POLICY: RA:HRPP:10.13 DATE EFFECTIVE: PAGE: 1 of 2 I. POLICY The Children s National Medical Center (CNMC) Human Research Protections Program (HRPP) recognizes
Clinical Investigator Training Course Investigator Responsibilities in Biomedical Research Covered by FDA Regulations Lisa Zimmerman Objectives Discuss Clinical Investigator Obligations according to FDA
Site visit inspection report on compliance with HTA minimum standards London School of Hygiene & Tropical Medicine HTA licensing number 12066 Licensed under the Human Tissue Act 2004 for the storage of
105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS Section 210.001: Purpose 210.002: Definitions 210.003: Policies Governing the Administration of Prescription
Documentation of the Informed Consent Process USC Office for the Protection of Research Subjects (OPRS) Session Overview Highlights: Purpose of Informed Consent (IC) IC Process and Documentation Witness
Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including
Orientation Manual for Clinical Research Coordinators Maine Medical Center Research Institute Page 1 of 19 Version 1 (2009) MAINE MEDICAL CENTER RESEARCH INSTITUTE Statement of Mission, Vision, Goals and
Site Initiation and Close Out (Sponsored Clinical Trials) Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 008 Version number: 1 Effective date: 01 June
Title Quality Assurance Inspections SOP Code 901.002 Effective Date 01-July-2016 Site Approvals Name and Title (typed or printed) Karine Morin Executive Director, Platforms Signature original signed Date
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Reporting of Adverse Events and Unanticipated Problems Policy date: 12/2011 Purpose The purpose of this policy is to ensure that the review, reporting and analysis of adverse events and unanticipated problems
PREP Course #27: Medical Device Clinical Trial Management Presented by: Evelyn Huang Jeffrey Revello Office of Research Compliance North Shore-LIJ Health System CME Disclosure Statement The North Shore
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD EMERGENCY MEDICINE RESEARCH EXEMPTION FROM INFORMED CONSENT REQUIREMENTS I. PURPOSE This document outlines the procedures for University
QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH Martin Valania, Executive Director, Corporate QA and Compliance Introduction Pharmaceutical companies recognize the benefits of carefully managing
Audit Findings in Clinical Trials: Avoiding the Pitfalls Kris West AVP A.V.P. & Director Office of Research Compliance Top Clinical Trial Audit Finding Areas Informed Consent Process & Documentation Accurate
CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion
STANDARD OPERATING PROCEDURE Site Initiation and Closeout Standard Operating Procedure Western Health SOP reference 008 Version: 2.0 dated December 2015 Effective Date Review Date Author: Approved by Mr
A robust feasibility is an essential part of ensuring study delivery. Please pass this Study Feasibility Assessment and a copy of the Protocol to the individual(s) who are most appropriate to accurately
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug
IRB Submissions and Human Subjects Research Compliance Offi f H R hp t ti Office of Human Research Protection Georgia Health Sciences University Objectives Identify the steps required to submit a protocol
Centralized vs Onsite Monitoring: A Sponsor s Balancing Act Applying a Risk-based Approach Introduction Since the August 2011 release of the draft guidance document by FDA on a risk-based approach to monitoring
9.0 Protocol Violations, Deviations, and Exceptions 9.1 Definitions Protocol deviation(s): means a minor or administrative departure from the IRBapproved protocol procedures (e.g., the protocol, informed
Quality Management System Manual This manual has been reviewed and approved for use by: Jack Zazulak President, Aurora Machine Limited March 07, 2011 Date - Copyright Notice - This document is the exclusive
QUALITY ASSURANCE MANUAL JPM OF MISSISSIPPI, INC. Hattiesburg, MS Revision E 01/19/11 Revised to ISO 9001:2008 on July 9, 2009 JPM OF MISSISSIPPI, INC. MANAGEMENT QUALITY POLICY It is the goal of JPM of
Office of Human Research Device Accountability in Clinical Research Managing research device inventory & tracking Objectives Define device accountability Review the two main categories of research devices
Far West Technology, Inc. ISO 9001 Quality Manual Document No.: QM Revision: 0 Issue Date: 27 August 1997 Approval Signatures President/CEO Executive Vice President Vice President/CFO Change Record Rev
AAHRPP Standards Investigator Responsibilities for Research Involving Human Subjects Regulatory Landscape 2 AAHRPP OHRP FDA Pennington Louisiana Laws The Association for the Accreditation of Human Research
Page 1 of 12 STATE OF CONNECTICUT REGULATION of State Department of Education Name of Agency Concerning Subject Matter of Regulations Administration of Medication by School Personnel and Administration
ICH CRA Certification Guide March 2009 ICH CRA CERTIFICATION GUIDE... 1 GENERAL INFORMATION... 2 BENEFITS OF CERTIFICATION... 2 INDUSTRY RECOGNITION... 2 ABOUT THE EXAM... 2 CRA DEFINITION... 2 REQUIREMENTS
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER
University of California Davis Investigator Manual Revised March 10, 2016 HRP-103 03/10/2016 2 of 41 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What
Table of Contents INTRODUCTION... i ACKNOWLEDGEMENTS... ii 1. Quality Management Program Overview... 1 Diagram of Quality Program Elements... 9 Sample Quality Management Performance Summary: Colorado Blood
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
Good Documentation Practices Clinical Research Operations & Regulatory Support Ann Glasse, RN, BSN, MBA Director, Regulatory Support Author: Johanna Stamates, RN, MA, CCRC, CHRC Objectives Recognize the
TABLE OF CONTENTS University of Northern Colorado HIPAA Policies and Procedures Page # Development and Maintenance of HIPAA Policies and Procedures... 1 Procedures for Updating HIPAA Policies and Procedures...
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Study Start-up
HR191 JOB DESCRIPTION NOTES Forms must be downloaded from the UCT website: http://forms.uct.ac.za/forms.htm This form serves as a template for the writing of job descriptions. A copy of this form is kept
CLOVER MACHINE AND MFG. 800 MATHEW ST. #101 SANTA CLARA, CA 95050 727-3380 727-7015 fax REVISION: DATE: PAGE 1 OF 45 QUALITY POLICY MANUAL DISTRIBUTION LIST: President Purchasing Manager Vice President